DCIS

United States Liquid Biopsy Market Report 2023 and 2024-2032 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad, Biocept, Biocartis, Myriad Genetics, Exact Sciences, NeoGenomics, Quest - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Surgery, Health, Genetics, Oncology, Liquid biopsy, Neoplasm, Nucleic acid thermodynamics, FDA, Urine, Breast cancer, CGP, NTRK, Prostate cancer, NIH, Woman, Blood, Entrectinib, Seminal vesicles, Gene, Liquid, Health care, Research, Plasma, Chinese, NGS, DNA, Lung, Incidence, Patient, Circulating tumor DNA, Diagnosis, Illumina, Inc., Biomarker, DCIS, NSCLC, Medical imaging

The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The United States Liquid Biopsy Market value is foreseen to be around US$ 3.68 Billion by 2032.
  • These innovations enhance cancer detection and monitoring and propel the United States liquid biopsy market.
  • Breast cancer might stand out as a distinguished concern in the United States liquid biopsy market.

Brixtel Defense Secures Prestigious Defense Contract for DCIS Ammunition Under DoD IG

Retrieved on: 
Tuesday, April 23, 2024
DCIS, Defense

GLENDIVE, Mont., April 23, 2024 /PRNewswire-PRWeb/ -- Washington, D.C. – Brixtel Defense is thrilled to announce its recent contract award to supply the Defense Criminal Investigative Service (DCIS) with critical 9mm and 5.56mm ammunition to NATO spec and Frangible training rounds under the oversight of the Department of Defense Inspector General (DoD IG). This significant award underscores Brixtel Defense's commitment to providing high-quality, reliable solutions to our nation's defense sectors.

Key Points: 
  • GLENDIVE, Mont., April 23, 2024 /PRNewswire-PRWeb/ -- Washington, D.C. – Brixtel Defense is thrilled to announce its recent contract award to supply the Defense Criminal Investigative Service (DCIS) with critical 9mm and 5.56mm ammunition to NATO spec and Frangible training rounds under the oversight of the Department of Defense Inspector General (DoD IG).
  • This significant award underscores Brixtel Defense's commitment to providing high-quality, reliable solutions to our nation's defense sectors.
  • "This contract is a testament to our relentless dedication to supporting the security and operational readiness of our federal agencies," said Andrew Mansoor, CEO of Brixtel Defense.
  • "This contract is a testament to our relentless dedication to supporting the security and operational readiness of our federal agencies," said Andrew Mansoor, CEO of Brixtel Defense.

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Comparison, Atossa, Patient, Mayo Clinic, Neoplasm, Ductal carcinoma, Woman, AACR, CFA, Clinical trial, Therapy, Breast cancer, Safety, DCIS, FDA, Exemestane, Breast, Annual general meeting, Pharmaceutical industry

SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.

Key Points: 
  • SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.
  • Full enrollment was achieved in November 2023 and data is expected in the second half of 2024.
  • Factors contributing to the increased operating expenses in the year ended December 31, 2023 are explained below.
  • The following table provides a breakdown of major categories within R&D expense for the years ended December 31, 2023 and 2022, together with the dollar change in those categories (in thousands):

Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Oncology, Medical Devices, Health, Genetics, Clinical Trials, Biotechnology, Survival, Patient, RNA, DNA, Cancer, University, Biology, Woman, AACR, Catalog, Breast cancer, MRD, DCIS, Blood, Medical imaging

Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting.

Key Points: 
  • Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting.
  • In addition, the study showed the platform’s unique capability to distinguish low grade, less aggressive DCIS from invasive breast cancer with 87% sensitivity, at 90% specificity using a standard blood sample.
  • These results suggest the potential for Exai's platform to aid in tailoring adjuvant treatment for individual triple negative breast cancer patients.
  • oncRNAs are actively secreted from living cancer cells and are stable and abundant in the blood of cancer patients.

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

Retrieved on: 
Thursday, February 22, 2024
Breast cancer, Woman, DCIS, Silicon, Ductal carcinoma, Risk, University, Biomarker, Therapy, Patient, University of California, Carcinoma in situ, Pharmaceutical industry

RECAST DCIS is an ongoing Phase 2 platform study designed to offer women diagnosed with DCIS six months of neoadjuvant endocrine therapy with the intent of determining their suitability for long-term active surveillance without surgery.

Key Points: 
  • RECAST DCIS is an ongoing Phase 2 platform study designed to offer women diagnosed with DCIS six months of neoadjuvant endocrine therapy with the intent of determining their suitability for long-term active surveillance without surgery.
  • A short 'explainer' video about Ductal Carcinoma In Situ and the RECAST DCIS study can be found here: DCIS Video Explainer.
  • “This is an overly aggressive treatment approach, especially when you consider most DCIS cases will not progress to invasive breast cancer if left untreated.
  • RECAST DCIS features the assessment of imaging and molecular-based biomarkers in addition to evaluating new investigational agents in this setting.

PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference

Retrieved on: 
Thursday, February 22, 2024
Cleveland Clinic, Therapy, DCIS, MD, IBR, MBCC, Conference, Radiation, Medicine, Patient, Impact, Radiation therapy, Woman, Medical imaging

LAGUNA HILLS, Calif., Feb. 22, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast Cancer Conference (MBCC), held on March 7 – 10, 2024 at the Fontainebleau, Miami Beach, FL.

Key Points: 
  • LAGUNA HILLS, Calif., Feb. 22, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast Cancer Conference (MBCC), held on March 7 – 10, 2024 at the Fontainebleau, Miami Beach, FL.
  • "We are excited to share data regarding our novel biosignature for invasive Stage I, II breast cancer test for radiation therapy, as well as clinical utility data on our DCISionRT test for DCIS at the prestigious MBCC conference," said Dan Forche, President and CEO of PreludeDx.
  • "We look forward to connecting with colleagues and sharing our vision for future early-stage breast cancer products, as well as advancing collaboration opportunities."
  • Title: Impact on Radiation Therapy Recommendation and Treatment Modality for Patients with Ductal Carcinoma in Situ Using the 7-Gene Biosignature: Analysis of the PREDICT Study
    Presenter: Chirag S. Shah, MD, Co-Director of Breast Radiation Oncology, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
    Title: Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-year Ipsilateral Breast Recurrence (IBR) Rates
    Presenter: Frank A. Vicini, MD, FASTRO, Radiation Oncologist at Michigan HealthCare Professionals, member of NRG Oncology

PreludeDx Appoints Chris Emery, VP of Strategic Marketing and Business Development

Retrieved on: 
Thursday, February 8, 2024
Pepperdine University, Ductal carcinoma, Novartis, DCIS, HALO, Patient, Labcorp, Molecular diagnostics, Marketing, Physician, Business development, Medicine, University, Cancer, Master of Business Administration, Medical imaging

LAGUNA HILLS, Calif., Feb. 8, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced the appointment of Chris Emery to the newly created position of VP of Strategic Marketing and Business Development.

Key Points: 
  • LAGUNA HILLS, Calif., Feb. 8, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced the appointment of Chris Emery to the newly created position of VP of Strategic Marketing and Business Development.
  • "With his extensive experience in healthcare and specifically molecular diagnostics, I am pleased to welcome Chris to PreludeDx's leadership team.
  • Chris brings more than 25 years of experience in healthcare across laboratory services, medical device and biopharmaceutical companies, with senior leadership roles in marketing, sales and business development in the cancer diagnostics market.
  • He joins PreludeDx from HALO Precision Diagnostics where he served as the Chief Business Officer – Molecular Diagnostics.

Atossa Therapeutics Issues Letter to Shareholders

Retrieved on: 
Tuesday, January 9, 2024
Woman, Weill Cornell Medicine, Research, Breast cancer screening, Share repurchase, Exemestane, University, Neoadjuvant therapy, Prognosis, Cancer, Breast, Risk, Breast Cancer Research Foundation, Cell death, University of California, Mastectomy, Ductal carcinoma, Diagnosis, Nature Portfolio, Growth, Silicon, Quantum Leap, Therapy, Neoplasm, BCRF, Seminal vesicles, Breast cancer, Disease, Patient, Lymph, Apoptosis, Radiation, Letter, Recurrence, TNBC, Phenotype, DCIS, PKC, Partnership, Mayo Clinic, Plasma, Triple-negative breast cancer, AKT, Springer Nature, FDA, Biomarker, PCR, Phosphorylation, Medical imaging

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:

Key Points: 
  • SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:
    2023 marked another year of significant progress for Atossa.
  • If you would like to learn more about the study, please visit www.atossatherapeutics.com to view a short video interview I conducted with Dr.
  • Adding to the issue is the fact that there are currently no approved treatments to reduce breast density.
  • On behalf of the board of directors, management, and employees of Atossa Therapeutics, we thank you for your investment and continued support of our Company.

PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, December 5, 2023
Patient, GenesisCare, Medicine, Ductal carcinoma, CP, RT, MBBS, DCIS, FRANZCR, Pharmaceutical industry

LAGUNA HILLS, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will present data demonstrating the decision impact on physician recommendations for radiation therapy (RT) in ductal carcinoma in situ (DCIS) patients in Australia.

Key Points: 
  • LAGUNA HILLS, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will present data demonstrating the decision impact on physician recommendations for radiation therapy (RT) in ductal carcinoma in situ (DCIS) patients in Australia.
  • The data will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), held on December 5 - 9, 2023 at the Henry B. Gonzalez Convention Center, San Antonio, Texas.
  • Specifically, in the interim analysis of 483-patients treated with breast conserving surgery in Australia, the use of the test resulted in a 41% change in RT recommendations and a 9% change in hormone therapy (HT) recommendations.
  • “The integration of DCISionRT into the clinical decision-making processes has a substantial impact on recommendations to personalize care and prevent over- and under-treatment,” said Dr. Yvonne Zissiadis, MBBS, FRANZCR, radiation oncologist, GenesisCare and principal investigator.

iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

Retrieved on: 
Monday, November 27, 2023
Radiology, Risk, Woman, Session, FDA, Death, Breast cancer, Ductal carcinoma, Breast, Hand tool, University, Overdiagnosis, DCIS, 2D, Karolinska Institute, High Risk, Digital, Physician, Inc., AI, CST, Neoplasm, Artificial intelligence, RSVP, Patient, Intelligence, Calcification, Partnership, Mammography, ICAD, Sale, Research, Blood, Biostatistics, CE, Google Health, Faculty, Cardiovascular disease, RSNA, Medical imaging

NASHUA, N.H., Nov. 27, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, will present new studies validating its artificial intelligence (AI) powered ProFound Breast Health Suite for uncovering hidden heart or vascular disease and predicting a woman’s risk for developing breast cancer in the next one- or two-years. Researchers will present their findings at the Radiological Society of North America’s (RSNA) annual meeting in Chicago, Nov. 27 – 30, 2023.

Key Points: 
  • Blending artificial intelligence with computer-aided detection (AI CAD), the iCAD software platform, ProFound Breast Health Suite, can screen a single mammogram for two of the top causes of death for women: breast cancer and heart disease.
  • In fact, women with breast arterial calcifications, or BAC, are 51% more likely to develop heart disease.
  • He and his colleagues found the ProFound Heart Health AI algorithm highly accurate in uncovering BAC in mammograms.
  • ProFound Heart Health***: a new solution for measuring cardiovascular calcium deposits, alerting to possible vascular or heart disease (pending FDA clearance).